AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio shares rose 7.2% on a share-repurchase program authorized to buy back up to $75 million of the company's common stock. Shares were recently trading around $18.31. The stock is down 15% over ...

Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...

Shares of AnaptysBio (NASDAQ: ANAB) climbed 12% today as the company announced a significant stock repurchase plan, signaling confidence in its financial position and future prospects. The ...

Intuitive Machines reported fourth-quarter revenue of $54.66 million, missing analyst estimates of $55.77 million, according ...

Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush issued their FY2029 earnings estimates for AnaptysBio in a research report issued to clients and investors ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses at week 14, with 69% of patients achieving ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...